485 related articles for article (PubMed ID: 18059438)
1. N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity.
Jensen NH; Rodriguiz RM; Caron MG; Wetsel WC; Rothman RB; Roth BL
Neuropsychopharmacology; 2008 Sep; 33(10):2303-12. PubMed ID: 18059438
[TBL] [Abstract][Full Text] [Related]
2. S32212, a novel serotonin type 2C receptor inverse agonist/α2-adrenoceptor antagonist and potential antidepressant: I. A mechanistic characterization.
Millan MJ; Mannoury la Cour C; Chanrion B; Dupuis DS; Di Cara B; Audinot V; Cussac D; Newman-Tancredi A; Kamal M; Boutin JA; Jockers R; Marin P; Bockaert J; Muller O; Dekeyne A; Lavielle G
J Pharmacol Exp Ther; 2012 Mar; 340(3):750-64. PubMed ID: 22178752
[TBL] [Abstract][Full Text] [Related]
3. SLV313 (1-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-4- [5-(4-fluoro-phenyl)-pyridin-3-ylmethyl]-piperazine monohydrochloride): a novel dopamine D2 receptor antagonist and 5-HT1A receptor agonist potential antipsychotic drug.
McCreary AC; Glennon JC; Ashby CR; Meltzer HY; Li Z; Reinders JH; Hesselink MB; Long SK; Herremans AH; van Stuivenberg H; Feenstra RW; Kruse CG
Neuropsychopharmacology; 2007 Jan; 32(1):78-94. PubMed ID: 16710314
[TBL] [Abstract][Full Text] [Related]
4. [Quetiapin in bipolar disorders].
Sümegi A
Neuropsychopharmacol Hung; 2008 Dec; 10(5):281-91. PubMed ID: 19419014
[TBL] [Abstract][Full Text] [Related]
5. Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT 2A receptors: functional receptor-binding and in vivo electrophysiological studies.
Stark AD; Jordan S; Allers KA; Bertekap RL; Chen R; Mistry Kannan T; Molski TF; Yocca FD; Sharp T; Kikuchi T; Burris KD
Psychopharmacology (Berl); 2007 Feb; 190(3):373-82. PubMed ID: 17242925
[TBL] [Abstract][Full Text] [Related]
6. Extended radioligand binding profile of iloperidone: a broad spectrum dopamine/serotonin/norepinephrine receptor antagonist for the management of psychotic disorders.
Kalkman HO; Subramanian N; Hoyer D
Neuropsychopharmacology; 2001 Dec; 25(6):904-14. PubMed ID: 11750183
[TBL] [Abstract][Full Text] [Related]
7. The quetiapine active metabolite N-desalkylquetiapine and the neurotensin NTS₁ receptor agonist PD149163 exhibit antidepressant-like effects on operant responding in male rats.
Hillhouse TM; Shankland Z; Matazel KS; Keiser AA; Prus AJ
Exp Clin Psychopharmacol; 2014 Dec; 22(6):548-56. PubMed ID: 25285844
[TBL] [Abstract][Full Text] [Related]
8. F15063, a potential antipsychotic with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. I. In vitro receptor affinity and efficacy profile.
Newman-Tancredi A; Assié MB; Martel JC; Cosi C; Slot LB; Palmier C; Rauly-Lestienne I; Colpaert F; Vacher B; Cussac D
Br J Pharmacol; 2007 May; 151(2):237-52. PubMed ID: 17375087
[TBL] [Abstract][Full Text] [Related]
9. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology.
Shapiro DA; Renock S; Arrington E; Chiodo LA; Liu LX; Sibley DR; Roth BL; Mailman R
Neuropsychopharmacology; 2003 Aug; 28(8):1400-11. PubMed ID: 12784105
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity.
Ishibashi T; Horisawa T; Tokuda K; Ishiyama T; Ogasa M; Tagashira R; Matsumoto K; Nishikawa H; Ueda Y; Toma S; Oki H; Tanno N; Saji I; Ito A; Ohno Y; Nakamura M
J Pharmacol Exp Ther; 2010 Jul; 334(1):171-81. PubMed ID: 20404009
[TBL] [Abstract][Full Text] [Related]
11. Affinity of cyamemazine metabolites for serotonin, histamine and dopamine receptor subtypes.
Benyamina A; Arbus C; Nuss P; Garay RP; Neliat G; Hameg A
Eur J Pharmacol; 2008 Jan; 578(2-3):142-7. PubMed ID: 17936750
[TBL] [Abstract][Full Text] [Related]
12. Norzotepine, a major metabolite of zotepine, exerts atypical antipsychotic-like and antidepressant-like actions through its potent inhibition of norepinephrine reuptake.
Shobo M; Kondo Y; Yamada H; Mihara T; Yamamoto N; Katsuoka M; Harada K; Ni K; Matsuoka N
J Pharmacol Exp Ther; 2010 Jun; 333(3):772-81. PubMed ID: 20223878
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological, neurochemical, and behavioral profile of JB-788, a new 5-HT1A agonist.
Picard M; Morisset S; Cloix JF; Bizot JC; Guerin M; Beneteau V; Guillaumet G; Hevor TK
Neuroscience; 2010 Sep; 169(3):1337-46. PubMed ID: 20580787
[TBL] [Abstract][Full Text] [Related]
14. Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
Bakken GV; Molden E; Knutsen K; Lunder N; Hermann M
Drug Metab Dispos; 2012 Sep; 40(9):1778-84. PubMed ID: 22688609
[TBL] [Abstract][Full Text] [Related]
15. New arylpiperazine 5-HT(1A) receptor ligands containing the pyrimido[2,1-f]purine fragment: synthesis, in vitro, and in vivo pharmacological evaluation.
Jurczyk S; Kołaczkowski M; Maryniak E; Zajdel P; Pawłowski M; Tatarczyńska E; Kłodzińska A; Chojnacka-Wójcik E; Bojarski AJ; Charakchieva-Minol S; Duszyńska B; Nowak G; Maciag D
J Med Chem; 2004 May; 47(10):2659-66. PubMed ID: 15115407
[TBL] [Abstract][Full Text] [Related]
16. PD 158771, a potential antipsychotic agent with D(2)/D(3) partial agonist and 5-HT(1A) agonist actions. I. Neurochemical effects.
Akunne HC; Zoski KT; Davis MD; Cooke LW; Meltzer LT; Whetzel SZ; Shih YH; Wustrow DJ; Wise LD; MacKenzie RG; Georgic LM; Heffner TG; Pugsley TA
Neuropharmacology; 2000 Apr; 39(7):1197-210. PubMed ID: 10760362
[TBL] [Abstract][Full Text] [Related]
17. S 15535, a novel benzodioxopiperazine ligand of serotonin (5-HT)1A receptors: I. Interaction with cloned human (h)5-HT1A, dopamine hD2/hD3 and h alpha2A-adrenergic receptors in relation to modulation of cortical monoamine release and activity in models of potential antidepressant activity.
Millan MJ; Newman-Tancredi A; Rivet JM; Brocco M; Lacroix P; Audinot V; Cistarelli L; Gobert A
J Pharmacol Exp Ther; 1997 Jul; 282(1):132-47. PubMed ID: 9223549
[TBL] [Abstract][Full Text] [Related]
18. WS-50030 [7-{4-[3-(1H-inden-3-yl)propyl]piperazin-1-yl}-1,3-benzoxazol-2(3H)-one]: a novel dopamine D2 receptor partial agonist/serotonin reuptake inhibitor with preclinical antipsychotic-like and antidepressant-like activity.
Brennan JA; Graf R; Grauer SM; Navarra RL; Pulicicchio CM; Hughes ZA; Lin Q; Wantuch C; Rosenzweig-Lipson S; Pruthi F; Lai M; Smith D; Goutier W; van de Neut M; Robichaud AJ; Rotella D; Feenstra RW; Kruse C; Broqua P; Beyer CE; McCreary AC; Pausch MH; Marquis KL
J Pharmacol Exp Ther; 2010 Jan; 332(1):190-201. PubMed ID: 19828876
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological profile of antipsychotics at monoamine receptors: atypicality beyond 5-HT2A receptor blockade.
Wood MD; Scott C; Clarke K; Cato KJ; Patel N; Heath J; Worby A; Gordon L; Campbell L; Riley G; Davies CH; Gribble A; Jones DN
CNS Neurol Disord Drug Targets; 2006 Aug; 5(4):445-52. PubMed ID: 16918396
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and pharmacological evaluation of azetedine and pyrrolidine derivatives as dual norepinephrine reuptake inhibitors and 5-HT(1A) partial agonists.
Pettersson M; Campbell BM; Dounay AB; Gray DL; Xie L; O'Donnell CJ; Stratman NC; Zoski K; Drummond E; Bora G; Probert A; Whisman T
Bioorg Med Chem Lett; 2011 Jan; 21(2):865-8. PubMed ID: 21185183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
